TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in range of knee movement (universal goniometer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in range of knee movement (mobile app)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Progression-free Survival at 18 Months
Endpoint domain: Mortality/survival
Primary endpoint: Response to numbness relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Restoration of sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Standard Uptake Value Maximum (SUVmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate maxillary expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration from CPB to ECS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in Actinic Keratosis lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: AK clearance of other body site lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement of daily living scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Eating Disorder Related Preoccupations and Rituals
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cost of care (PMPM savings)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sound quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Inflammatory Acne Lesions From Baseline to Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent Change in Non-inflammatory Acne Lesions From Baseline to Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent Change in Total Acne Lesion Counts From Baseline to Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Investigator Global Assessment (IGA)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in elbow pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Synchronization status change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response latency during picture naming task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ropivacaine plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased HIV testing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased number of sexual risk behaviors
Endpoint domain: Life impact
Endpoint subdomain: Risk behaviors
Primary endpoint: Upper lid height before and after phenylephrine test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower lid height before and after phenylephrine test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mean Trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With at Least 1 Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Insomnia Severity Index (ISI) score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in the amount of sleep obtained
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Invasive breast cancer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of SARS-CoV-2 load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Invasive disease free survival
Endpoint domain: Mortality/survival
Primary endpoint: Unintended pregnancies
Endpoint domain: Mortality/survival
Primary endpoint: Rate of neurological deficit score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of abstainer patients and patients with low risk consumption
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percentage of deaths occurred in the hospital
Endpoint domain: Mortality/survival
Primary endpoint: Composite Rate of Cardiac Death and Target Vessel Myocardial Infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: Volume of pneumothorax at CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Abcess
Endpoint domain: Adverse events/effects
Primary endpoint: Fistula
Endpoint domain: Adverse events/effects
Primary endpoint: lamina dura
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periapical radiographic radiolucency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Troponin I Leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Number of Participants Affected
Endpoint domain: Adverse events/effects
Primary endpoint: Annualized Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Miller synechia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best corrected visual acuity gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endogenous melatonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG slow-wave activity (SWA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Clinical Opiate Withdrawal Scale (COWS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of change in human placental lactogen concentration in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: hospitalization for decompensated heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in tinnitus complaints
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cmax of Sulforaphane and Its Metabolites in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of Sulforaphane and Its Metabolites in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnesium cellular levels correlation with antiinflammatory indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of unacceptable adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients alive
Endpoint domain: Mortality/survival
Primary endpoint: Epigenetic signatures associated with response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total incidence and rate of grade 3 and 4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of Acelarin in combination with Cisplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Port-A wound healing/infection status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Function of the upper extremity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Levels of Interleukins 1 and 6 and Tumor Necrosis Factor Alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of circulating tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cohen-Mansfield Agitation Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain in Dementia Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social Interaction Tool
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Tolerability of VPA in combination with low dose CdA
Endpoint domain: Adverse events/effects
Primary endpoint: Mean of cognitive subjective effort parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Differences between cognitive subjective effort parameters before and after fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean of physical subjective effort parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Differences between physical subjective effort parameters before and after fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Toxicity evaluation
Endpoint domain: Adverse events/effects
Primary endpoint: Mean deviation changes on SAP and SWAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of HIV-1 infections per 100 person-years
Endpoint domain: Mortality/survival
Primary endpoint: Post-infection viral load and CD4 count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Superiority of catheter ablation over amiodarone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the curve to the last quantifiable measurement (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal fat mass changes during pregnancy and postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infant percent fat at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absence of the ECG Br pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: occurrence of major adverse cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: occurrence of major or minor bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of esophageal adenocarcinomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of overall symptomatic VTE recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of participants experiencing Real World Safety Data Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Unified Parkinson's Disease Rating Scale III (UPDRS-III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Incidence of drug-related dose-limiting toxicity (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Thrombocyte aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Erectile Hardness Score (EHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Index of Erectile Function (IIEF-5) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vascular Endothelial Growth Factor (VEGF) level in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axonal Excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of pharyngeal reflux/24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of pharyngeal acid reflux/24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pharyngeal acid exposure (% of total time with pharyngeal pH <4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pharyngeal bolus exposure (% of total time with liquid in the pharynx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Anxiety measured by Hospital Anxiety and Depression Scale (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety measured by Edmonton Symptom Assessment System (ESAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity to rectal distention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Physician's Assessment of Efficacy of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Incidence of Specified Cardiovascular Events in Omega-3 Fatty Acid Users
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative Incidence of Specified Cardiovascular Events in Omega-3 Fatty Acid Non-Users
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Core stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapist Competency and Adherence Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tremor Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Protocol Adherence Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Occurrence of plasma glucose < 60 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants with Major Adverse Events within 30 days of the procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in degree of tricuspid regurgitation measured immediately after the procedure compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in degree of tricuspid regurgitation measured at time of discharge compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anti-mullerian hormone (AMH) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: engagement duration for an activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AUCtau of ATV, DRV, TAF, and TFV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing Treatment Emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Treatment Emergent Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in Proportion of Waking Day Spent in Off
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medial longitudinal arch height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intentions to positively intervene in adolescent relationship abuse among peers
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knowledge of violence victimization resources
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: weight gain following diagnosis of breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of new vascular events or death
Endpoint domain: Mortality/survival
Primary endpoint: Anti-hepatitis B surface antigen (HBs) antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measurement of plasma peptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Visual Analogue Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gut Microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methamphetamine Use, Measured by Number of Consecutive Days of Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Functional Independence Measure (WeeFIM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Manual muscle testing (MMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serum Alkaline Phosphatase (SAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung lining fluid cell count and differential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Degree of Plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of Gingivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of Gingival Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of not completing the procedure due to patient's discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: Observed thermal damage on skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Grade 3 or 4 toxicities assessed by the National Cancer Institute (NCI) Common Toxicity Criteria (CTC)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical grade of radioactive oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasonic visualization grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Distance between the midline and the expected location of needle insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Depth from skin to LFD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diagnosis of specific pattern of LDS in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of islets necessary to achieve adequate metabolic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: post-transplant islet function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change Over Time in Viral Antigens and DNA in CHB Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) for AZD9496 and Its Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Time With Last Observation (AUC0-t) for AZD9496 and Its Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CIPN grade >1
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of focal ablation of targeted prostate lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Sodium Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fructose expiration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute graft vs. host disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of correct responses regarding risks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response to transarterial chemoembolization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with pain following nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK parameters of ivacaftor and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK parameters of VX-661 and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in granulosa cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in follicle count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in follicular size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: PASI score improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevalence of intensive care unit delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Avoidable Emergency Room Visit Rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Avoidable In-Patient Visit Rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: pain incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of intrapartum GBS real time PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Positive predictive value of GBS Real time PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Specificity of intrapartum GBS real time PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Central Subfield Thickness (CST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Abnormal Laboratory Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global developmental delays in young children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-linguistic communication and lexicon emergence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in neural flavor cue-reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Lipidome Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes